描述:與全反式維甲酸(ATRA)不同,EC23在溶液狀態(tài)下對光線、加熱和空氣都不敏感。EC23不溶于水,微溶于乙醇,可以DMSO配制10mg/mL母液,或者以95%乙醇配制0.33mg/mL的母液,需要漩渦助溶。后續(xù)可溶于水溶液(包括細胞培養(yǎng)基)。溶液形式的EC23不會降解,保存EC23溶液時不必特別注意避光密封
理想而穩(wěn)定的維甲酸(ATRA)替代物 |
添加時間:2012-1-4 14:35:48 |
貨號:SRP001 品名:合成的類維A酸 EC23 (4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylethynyl) benzoic acid) 物理特性: 外觀:白色粉末 分子式:C23H24O2 分子量:332 純度:99%(HPLC) 保存: 合成的類維A酸 EC23可以在常規(guī)實驗室條件下保持化學/物理性質(zhì)的穩(wěn)定。 可溶性: 與全反式維甲酸(ATRA)不同,EC23在溶液狀態(tài)下對光線、加熱和空氣都不敏感。EC23不溶于水,微溶于乙醇,可以DMSO配制10mg/mL母液,或者以95%乙醇配制0.33mg/mL的母液,需要漩渦助溶。后續(xù)可溶于水溶液(包括細胞培養(yǎng)基)。溶液形式的EC23不會降解,保存EC23溶液時不必特別注意避光密封。 應(yīng)用: EC23僅限科研使用,不可用于臨床。實驗表明,該化合物可以強力的誘導(dǎo)多能干細胞向神經(jīng)組織方向分化,與ATRA相比,EC23能夠穩(wěn)定的誘導(dǎo)大量神經(jīng)元分化。此外,EC23還能激活Hox基因轉(zhuǎn)錄子的表達。 參考文獻:
|
Differentiating neurons from stem cells just got easier. | |
Some retinoids can be troublesome, their lack of stability in light and susceptibility to degradation means it is impossible to know what dose you are really working with. ec23 is compley stable and the dose you add to your culture is exactly what you think it isevery time. For ease of use, ec23 comes in a clear glass vial. No more searching for your retinoid in dark glass. ec23 is a stable, synthetic retinoid which has been shown to be a potent inducer of both pluripotent stem cell and adult neuroprogenitor cell differentiation across a range of species.1-5
|
More neurons less guess work
|
ec23 is stable; NMR of ec23 during prolonged exposure to light demonstrates clearly ec23 remains compley intact.
1H NMR (500 MHz) spectrum (δ 7.20-8.10) of ec23 in D16-DMSO in a glass NMR tube after 3 days in the dark under air (top), versus 3 days exposure to fluorescent light (bottom).
Catalogue number | Product description | Pack size | ||
SRP002 | ec23 | 5mg | Download Reinnervate Flyer (PDF) |
To order contact your local LGC Standards office or atcc@lgcstandards.com
Selected publications
1.Christie V.B., et al (2008). Organic and Biomolecular Chemistry, 6, 3497-3507.
2.Blow, N. (2008). Nature, 451, 855-858.
3.Przyborski S.A. (2008). European Pharmaceutical Review, 6, 36-39.
4.Barnard, J.H., et al (2009). Chemistry, 15, 11430-52.
5.Maltman, D.J., et al (2009). Molecular Biosystems, 5, 458-471.